Fund Holdings — Lynx1 Capital Management LP

Total Portfolio Value
$282.24M
Total Bought
$59.83M
Total Sold
$8.77M
Net Transaction
+$51.06M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q2 2024
▲▼
Q3 2024
▲▼
Change
▲▼
Q2 2024
▲▼
Q3 2024
▲▼
Weight (%)
▲▼
Change
▲▼
MERUS N V1,206,7071,793,866+587,15971,40189,62231.75%+18,221
ALLOGENE THERAPEUTICS INC2,228,2956,202,374+3,974,0795,19217,3676.15%+12,175
C4 THERAPEUTICS INC(CCCC)6,880,5276,880,527031,78839,21913.90%+7,431
PASSAGE BIO INC(PASG)5,057,6298,426,955+3,369,3264,0175,8992.09%+1,882
CARIBOU BIOSCIENCES INC(CRBU)0680,189+680,18901,3330.47%+1,333
KODIAK SCIENCES INC(KOD)0271,177+271,17707080.25%+708
IBIO INC(IBIO)600,000862,279+262,2791,2661,9140.68%+648
CULLINAN THERAPEUTICS INC(CGEM)377,323410,830+33,5076,5816,8772.44%+297
PIERIS PHARMACEUTICALS INC43,49937,436-6,0634276210.22%+194
CENTESSA PHARMACEUTICALS PLC17,40017,40001572780.10%+121
TENAX THERAPEUTICS INC(TENX)014,751+14,7510510.02%+51
CENTURY THERAPEUTICS INC(IPSC)019,028+19,0280330.01%+33
KINIKSA PHARMACEUTICALS INTL(KNSA)9,5008,231-1,2691772060.07%+28
VYNE THERAPEUTICS INC(YARW)16,19416,194032300.01%-1
KORRO BIO INC(KRRO)3,8000-3,8001290—-129
BIONOMICS LIMITED599,673549,673-50,0004602410.09%-218
CABALETTA BIO INC(CABA)492,1030-492,1033,6810—-3,681
LONGBOARD PHARMACEUTICALS IN167,3170-167,3174,5230—-4,523
TSCAN THERAPEUTICS INC(TCRX)5,224,6005,224,600030,56426,0199.22%-4,545
STOKE THERAPEUTICS INC(STOK)5,185,1915,187,191+2,00070,05263,75122.59%-6,301
GH RESEARCH PLC(GHRS)3,966,7264,195,894+229,16846,25228,0719.95%-18,181
Page 1 of 1
Lynx1 Capital Management LP — 13F Holdings — Q3 2024 | TickerTrail